Cargando…

Superior reductions in hepatic steatosis and fibrosis with co-administration of a glucagon-like peptide-1 receptor agonist and obeticholic acid in mice

OBJECTIVE: Nonalcoholic steatohepatitis (NASH) is an unmet need associated with metabolic syndrome. There are no approved therapies for NASH; however, glucagon-like peptide-1 receptor (GLP-1R) and farnesoid-X receptor (FXR) agonists are promising drug targets. We investigated the therapeutic effects...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jouihan, Hani, Will, Sarah, Guionaud, Silvia, Boland, Michelle L., Oldham, Stephanie, Ravn, Peter, Celeste, Anthony, Trevaskis, James L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5681275/ https://www.ncbi.nlm.nih.gov/pubmed/29107284 http://dx.doi.org/10.1016/j.molmet.2017.09.001

Ejemplares similares

Nonalcoholic steatohepatitis severity is defined by a failure in compensatory antioxidant capacity in the setting of mitochondrial dysfunction
por: Boland, Michelle L, et al.
Publicado: (2018)

Obeticholic acid ameliorates obesity and hepatic steatosis by activating brown fat
por: Zhang, Hanlin, et al.
Publicado: (2021)

Resolution of NASH and hepatic fibrosis by the GLP-1R/GcgR dual-agonist Cotadutide via modulating mitochondrial function and lipogenesis.
por: Boland, Michelle L., et al.
Publicado: (2020)

The FXR agonist obeticholic acid inhibits the cancerogenic potential of human cholangiocarcinoma
por: Di Matteo, S., et al.
Publicado: (2019)

FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis
por: Verbeke, Len, et al.
Publicado: (2016)

Combined obeticholic acid and apoptosis inhibitor treatment alleviates liver fibrosis
por: Zhou, Jiyu, et al.
Publicado: (2019)

Unaltered Liver Regeneration in Post-Cholestatic Rats Treated with the FXR Agonist Obeticholic Acid
por: de Haan, Lianne R., et al.
Publicado: (2021)

Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis
por: Parés, Albert, et al.
Publicado: (2020)

FXR agonist obeticholic acid induces liver growth but exacerbates biliary injury in rats with obstructive cholestasis
por: van Golen, Rowan F., et al.
Publicado: (2018)

Obeticholic acid for primary biliary cholangitis
Publicado: (2020)

Obeticholic Acid for Primary Biliary Cholangitis
por: Floreani, Annarosa, et al.
Publicado: (2022)

Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes
por: Kjeldsen, Sasha A S, et al.
Publicado: (2023)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Robust anti‐obesity and metabolic effects of a dual GLP‐1/glucagon receptor peptide agonist in rodents and non‐human primates
por: Henderson, S. J., et al.
Publicado: (2016)

Caenorhabditis Intervention Testing Program: the farnesoid X receptor agonist obeticholic acid does not robustly extend lifespan in nematodes
por: Morshead, Mackenzie L, et al.
Publicado: (2020)

Obeticholic acid, a selective farnesoid X receptor agonist, regulates bile acid homeostasis in sandwich‐cultured human hepatocytes
por: Zhang, Yuanyuan, et al.
Publicado: (2017)

The FXR Agonist, Obeticholic Acid, Suppresses HCC Proliferation & Metastasis: Role of IL-6/STAT3 Signalling Pathway
por: Attia, Yasmeen M., et al.
Publicado: (2017)

Obeticholic acid protects against hepatocyte death and liver fibrosis in a murine model of nonalcoholic steatohepatitis
por: Goto, Toshihiro, et al.
Publicado: (2018)

Treatment of Nonalcoholic Steatohepatitis by Obeticholic Acid: Current Status
por: Roy, Partho Pratik, et al.
Publicado: (2022)

Clarification of Obeticholic Acid Dosing: Response to “Occurrence of Jaundice Following Simultaneous Ursodeoxycholic Acid Cessation and Obeticholic Acid Initiation” by Quigley et al.
por: Feng, Cynthia
Publicado: (2018)

The protective effect and mechanism of the FXR agonist obeticholic acid via targeting gut microbiota in non-alcoholic fatty liver disease
por: Zhang, Dan-Ying, et al.
Publicado: (2019)

Real‐World Effectiveness of Obeticholic Acid in Patients with Primary Biliary Cholangitis
por: Roberts, Surain B., et al.
Publicado: (2020)

Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites
por: Yan, Kathleen, et al.
Publicado: (2021)

Differential Effects of a Glucagon-Like Peptide 1 Receptor Agonist in Non-Alcoholic Fatty Liver Disease and in Response to Hepatectomy
por: Valdecantos, M. Pilar, et al.
Publicado: (2018)

Obeticholic Acid Induces Hepatoxicity Via FXR in the NAFLD Mice
por: Lin, Chuangzhen, et al.
Publicado: (2022)

Obeticholic acid treatment ameliorates the cardiac dysfunction in NASH mice
por: Liu, Szu-Yu, et al.
Publicado: (2022)

Co-administration of obeticholic acid and simvastatin protects against high-fat diet-induced non-alcoholic steatohepatitis in mice
por: Li, Wen-Cong, et al.
Publicado: (2021)

The molecular pharmacology of glucagon agonists in diabetes and obesity
por: Novikoff, Aaron, et al.
Publicado: (2023)

Acute plasma amylase increase after glucagon‐like peptide ‐1 receptor agonist exenatide administration in Type 2 diabetes
por: Smits, M. M., et al.
Publicado: (2017)

miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
por: Rodrigues, Pedro M, et al.
Publicado: (2017)

miR-21 ablation and obeticholic acid ameliorate nonalcoholic steatohepatitis in mice
por: Rodrigues, Pedro M, et al.
Publicado: (2017)

Metabolic Profile of Obeticholic Acid and Endogenous Bile Acids in Rats with Decompensated Liver Cirrhosis
por: Roda, A, et al.
Publicado: (2017)

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease
por: Makri, Evangelia, et al.
Publicado: (2016)

Modeling and Experimental Studies of Obeticholic Acid Exposure and the Impact of Cirrhosis Stage
por: Edwards, JE, et al.
Publicado: (2016)

New developments in the treatment of primary biliary cholangitis – role of obeticholic acid
por: Jhaveri, Manan A, et al.
Publicado: (2017)

Real-world experience with obeticholic acid in patients with primary biliary cholangitis
por: D’Amato, Daphne, et al.
Publicado: (2021)

Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis
por: Winther-Sørensen, Marie, et al.
Publicado: (2020)

Changes in Indices of Steatosis and Fibrosis in Liver Grafts of Living Donors After Weight Reduction
por: Choi, Jaehyuk, et al.
Publicado: (2022)

The farnesoid X receptor agonist obeticholic acid upregulates biliary excretion of asymmetric dimethylarginine via MATE-1 during hepatic ischemia/reperfusion injury
por: Ferrigno, Andrea, et al.
Publicado: (2018)

Obeticholic acid for the treatment of primary biliary cholangitis in adult patients: clinical utility and patient selection
por: Bowlus, Christopher L
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kpbkh8fo7fuc4jo50qlkr1redt